Long-Term Follow-Up Results of an Ongoing Pivotal Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

摘要

Scott E. Smith, MD, PhD, presented the long-term follow-up results of an ongoing study of patients with relapsed or refractory HL.1 Survival is lower for patients with relapsed HL than it is for patients with other forms of HL, and the survival curves look dramatically different. Relapse does occur in approximately 50% of patients, resulting in poor to moderate OS. After autologous stem cell transplant (ASCT), the median survival is 2.4 years among patients who relapse less than 1 year after ASCT.2 These patients live an average of 1.2 years.